Published in:
01-01-2013 | Correspondence
Artesunate- and Amodiaquine-Associated Extrapyramidal Reactions
Information Gained from an African-Based Risk Management Plan
Author:
François Bompart
Published in:
Drug Safety
|
Issue 1/2013
Login to get access
Excerpt
In an article recently published in
Drug Safety [
1], McEwen mentions that “… the Summary of Product Characteristics (SPC) for Artesunate Amodiaquine Winthrop
® refers to somnolence, paraesthesias, headache, dizziness, convulsion and rare neuromyopathy. There is no mention of movement disorders, extrapyramidal disorders or their common pathognomonic symptoms, which is curious as the SPC purports to include additional types of events that have been attributed to amodiaquine in the published literature”. I think it may be helpful to provide further information on this. …